Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.86 |
| ▸ | ATM | Q13315 | 1/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10462008 | 0.99 | L3MBTL1 (0.84) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| Cadaverine Tartrate SCHEMBL27494555 | 0.93 | L3MBTL1 (0.76) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL14022760 | 0.92 | L3MBTL1 (0.74) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL1545229 | 0.92 | L3MBTL1 (0.74) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL8263564 | 0.92 | L3MBTL1 (0.74) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL3317577 | 0.90 | L3MBTL1 (0.71) | L3MBTL1ATMKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8250801 | 0.90 | ALDH1A1 (0.80) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL4850083 | 0.89 | ALDH1A1 (0.78) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL10016602 | 0.88 | KDM4E (1.00) | L3MBTL1ATMKDM4EALDH1A1TDP1 | |
| SCHEMBL6183167 | 0.88 | L3MBTL1 (0.69) | L3MBTL1ATMKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2021188949-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3555094-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109198-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-6664271-B1 | Amide, carbamate and uredo derivatives of 3-piperidine-carboxylic acid or ester; protecting against infection by such as escherichia coli and/or actinobacillus pleuropneumoniae | ELI LILLY AND COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
| CN-1174504-A | Piperidines, pyrrolidines and hexahydro -1H -azepines promote release of growth hormone | MERCK & CO INC (US) | 1998-02-25 | — | — | CN | disclosed |
| EP-0287356-B1 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5132316-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1992-07-21 | — | — | US | disclosed |
| US-4971975-A | TREATMENT OF DEMENTIA; AZABICYCLOOCTANE COMPOUNDS | BEECHAM GROUP PLC (GB) | 1990-11-20 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | L3MBTL1 4328/4885ATM 3373/4885KDM4E 4020/4885 |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | L3MBTL1 2010/4885ATM 4545/4885KDM4E 4370/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | L3MBTL1 1959/4885ATM 4586/4885KDM4E 4220/4885 |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | L3MBTL1 1054/4885ATM 482/4885KDM4E 364/4885 |
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | L3MBTL1 2527/4885ATM 2219/4885KDM4E 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.